Kolon Life Science Q1 Operating Profit Turns Black, Equity Surges

Consolidated revenue KRW 49.6bn (+10.8% YoY), operating profit KRW 2.9bn (turnaround from KRW 0.07bn in prior year Q1)
Net income for the quarter KRW 20.8bn (down from KRW 25.0bn in prior year Q1), total equity KRW 784.1bn (+34% from year-end 2025) – reflects fair value gains on FVOCI financial assets (Kolon TissueGene shares)
TG-C (Invossa) technology export contract: total up to KRW 723.4bn with Pine Pharmaceuticals, upfront KRW 15bn received
Bio business continues operating loss of KRW 6.4bn; KLS-2031 phase 1/2a paper published, diabetic neuropathic pain preclinical paper submitted
Invossa product license revocation lawsuit ongoing; 32 damage claim lawsuits pending (provision recognized)
All series 6 convertible bonds (KRW 12bn) converted; issuance of series 3 and 9 hybrid bonds (total KRW 55bn) bolstered capital
No dividends or share buyback/cancellation